The Food and Drug Administration's Division of Psychiatry Products placed a full clinical hold on Alcobra Ltd.'s (Nasdaq: ADHD) Investigational New Drug applications for MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome sending the stock price plummeting $2.11 to close at $2.51.
Clinical hold placed on Alcobra's MDX
September 29, 2016 at 17:45 PM EDT
